Viatris (VTRS) Competitors

Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Takeda Pharmaceutical had 5 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 1 mentions for Viatris. Takeda Pharmaceutical's average media sentiment score of 0.66 beat Viatris' score of 0.00 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.6%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.9%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -133.3% of its earnings in the form of a dividend. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Takeda Pharmaceutical has a net margin of 3.80% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Takeda Pharmaceutical's return on equity.

Viatris has a consensus target price of $18.57, indicating a potential upside of 12.93%. Given Viatris' higher probable upside, analysts clearly believe Viatris is more favorable than Takeda Pharmaceutical.

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Teva Pharmaceutical Industries has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Viatris presently has a consensus target price of $18.57, indicating a potential upside of 12.93%. Teva Pharmaceutical Industries has a consensus target price of $43.10, indicating a potential upside of 17.49%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Viatris.

In the previous week, Teva Pharmaceutical Industries had 22 more articles in the media than Viatris. MarketBeat recorded 23 mentions for Teva Pharmaceutical Industries and 1 mentions for Viatris. Teva Pharmaceutical Industries' average media sentiment score of 0.87 beat Viatris' score of 0.00 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

79.9% of Viatris shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Viatris' net margin of -2.79%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Viatris' return on equity.

Viatris has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, BeOne Medicines had 9 more articles in the media than Viatris. MarketBeat recorded 10 mentions for BeOne Medicines and 1 mentions for Viatris. BeOne Medicines' average media sentiment score of 0.97 beat Viatris' score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the news media.

Viatris currently has a consensus price target of $18.57, indicating a potential upside of 12.93%. BeOne Medicines has a consensus price target of $402.14, indicating a potential upside of 14.93%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Viatris.

BeOne Medicines has a net margin of 10.70% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat BeOne Medicines' return on equity.

BeOne Medicines has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Viatris has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Royalty Pharma presently has a consensus target price of $61.29, suggesting a potential upside of 1.45%. Viatris has a consensus target price of $18.57, suggesting a potential upside of 12.93%. Given Viatris' higher possible upside, analysts clearly believe Viatris is more favorable than Royalty Pharma.

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Royalty Pharma has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Viatris has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

In the previous week, Royalty Pharma had 8 more articles in the media than Viatris. MarketBeat recorded 9 mentions for Royalty Pharma and 1 mentions for Viatris. Royalty Pharma's average media sentiment score of 0.52 beat Viatris' score of 0.00 indicating that Royalty Pharma is being referred to more favorably in the media.

Royalty Pharma has a net margin of 32.14% compared to Viatris' net margin of -2.79%. Royalty Pharma's return on equity of 30.01% beat Viatris' return on equity.

Royalty Pharma has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.9%. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Viatris pays out -133.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.